NANOV Stock Overview
Nordic Nanovector ASA, a biopharmaceutical company, develops therapeutics for hematological cancers in Norway. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Nordic Nanovector ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 2.00 |
| 52 Week High | NOK 3.34 |
| 52 Week Low | NOK 0.65 |
| Beta | 1.61 |
| 11 Month Change | 167.11% |
| 3 Month Change | 149.44% |
| 1 Year Change | -22.20% |
| 33 Year Change | -90.38% |
| 5 Year Change | -96.64% |
| Change since IPO | -92.86% |
Recent News & Updates
Recent updates
Can Nordic Nanovector (OB:NANOV) Afford To Invest In Growth?
Aug 30
Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?
Nov 09We Think Nordic Nanovector (OB:NANOV) Needs To Drive Business Growth Carefully
Jul 02Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?
Jan 06Shareholder Returns
| NANOV | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -18.3% | 8.9% | 3.1% |
| 1Y | -22.2% | -69.4% | 3.9% |
Return vs Industry: NANOV exceeded the Norwegian Biotechs industry which returned -61.9% over the past year.
Return vs Market: NANOV underperformed the Norwegian Market which returned -0.1% over the past year.
Price Volatility
| NANOV volatility | |
|---|---|
| NANOV Average Weekly Movement | 39.3% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in NO Market | 10.6% |
| 10% least volatile stocks in NO Market | 2.7% |
Stable Share Price: NANOV's share price has been volatile over the past 3 months.
Volatility Over Time: NANOV's weekly volatility has increased from 24% to 39% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 18 | Alf Bjornseth | www.nordicnanovector.com |
Nordic Nanovector ASA, a biopharmaceutical company, develops therapeutics for hematological cancers in Norway. The company’s lead product candidate is Betalutin, a CD37-targeting radioimmunotherapy for the treatment of patients with non-hodgkin lymphoma. Its preclinical development products include Humalutin for treatment of non-Hodgkin’s lymphoma; Alpha37, a CD37-targeting radioimmunotherapy for treating chronic lymphatic leukemia; and Multiple fully humanized anti-CD37 antibodies for treatment of haematological cancers and autoimmune diseases.
Nordic Nanovector ASA Fundamentals Summary
| NANOV fundamental statistics | |
|---|---|
| Market cap | NOK 231.84m |
| Earnings (TTM) | -NOK 311.24m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs NANOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NANOV income statement (TTM) | |
|---|---|
| Revenue | NOK 0 |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 0 |
| Other Expenses | NOK 311.24m |
| Earnings | -NOK 311.24m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
Aug 31, 2023
| Earnings per share (EPS) | -2.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NANOV perform over the long term?
See historical performance and comparison